NCT00485966 - Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Study Completion Date

June 30, 2008

Conditions

B-Cell Chronic Lymphocytic Leukemia

Interventions

DRUG

CX-3543

360 mg/m2 daily x 5 q 21 days

Trial Locations (7)

Gundersen Lutheran Medical Center, La Crosse

Cancer Therapy and Research Center, San Antonio

South Texas Accelerated Research Therapeutics (START), San Antonio

Mayo Clinic, Scottsdale

Tower Cancer Research Foundation, Beverly Hills

University of New Mexico Cancer Research and Treatment Center, Albuquerque

Oregon Health and Sciences University, Portland